[A new target of cancer therapy: advances in the study of histone deacetylase].
Liu
Ai-Lin
AL
Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Long
Juan
J
Wang
Nan
N
Du
Guan-Hua
GH
D000107:Acetylation; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D001549:Benzamides / Q000494:pharmacology; D016503:Drug Delivery Systems; D004791:Enzyme Inhibitors / Q000494:pharmacology; D051548:Histone Acetyltransferases / Q000187:drug effects / Q000378:metabolism; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000737:chemistry / Q000502:physiology; D006657:Histones / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D009369:Neoplasms / Q000473:pathology*; D010455:Peptides / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D014635:Valproic Acid / Q000494:pharmacology
D001549:Benzamides; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006657:Histones; D006877:Hydroxamic Acids; D010455:Peptides; D011725:Pyridines; C067070:trapoxin A; C118739:entinostat; C012589:trichostatin A; D014635:Valproic Acid; D051548:Histone Acetyltransferases; D006655:Histone Deacetylases